Bacterial biofilms are resistant to most of the commonly available antibacterial chemotherapies. Thus, an enormous need exists to meet the demands of effective anti-biofilm therapy. In this study, a small library of cinchona alkaloids, including the naturally occurring compounds cinchonidine and cinchonine, as well as various synthetic derivatives and analogues was screened for antibacterial and anti-biofilm activity against the Staphylococcus aureus biofilm producing strain ATCC 25923. Two methods were used to evaluate activity against biofilms, namely crystal violet staining to measure biomass and resazurin assay to measure biofilms viability. Cinchonidine was found to be inactive, whereas a synthetic derivative, 11-triphenylsilyl-10,11-dihydrocinchonidine (11-TPSCD), was effective against planktonic bacteria as well as in preventing biofilm formation at low micromolar concentrations. Higher concentrations were required to eradicate mature biofilms.
Bacteria are known to exist in two main lifestyles: planktonic (single-cell, also called suspensions) and biofilms (multicellular form). In nature, however, the majority of all known bacteria exist mainly as biofilms. Bacterial biofilms refer to surface-attached communities, typically described as bacteria embedded in a selfproduced matrix that consists of extracellular polysaccharides, DNA and proteins in a varying composition that is species or even strain dependent [1a] . Their most relevant feature is that they exhibit increased resistance towards antimicrobial therapy [1b] when compared with planktonic bacteria. For example, biofilms produced by Staphylococcus aureus are a leading cause of nosocomial diseases, including infections in prosthetic devices and catheters [1c] . Up to date, a limited number of antimicrobials capable of effectively killing mature Staphylococcus spp. biofilms has been reported [2a] . Thus, a great need exists to meet the demands of effective anti-biofilm therapy.
Nature is still the major source of new drug compounds and, hence, natural products offer a well-justified starting point for identifying novel drug candidates [2b] . Cinchona alkaloids are present in the bark of Cinchona species and include compounds reported to display a wide range of biological activities with quinine (QN) being one of the most studied as a chemotherapeutic agent with well-known effects as an anti-malarial drug [2c,3] . Quinine and its derivatives also display bactericidal effects against methicillinresistant suspensions of Staphylococcus aureus [4, 5] . Moreover, quinine is a structural template for the quinolone antibiotics [6] . In fact, quinolone antibiotics have also been found to act against bacterial biofilms, albeit at higher concentrations [7,8a] . Cinchonidine (CD), another naturally occurring cinchona alkaloid that differs from quinine by the lack of the methoxy group in the 6'-position of the quinoline aromatic ring system, has also been reported to display anti-malarial properties [8b], but much less is known of its antibacterial effects. In this contribution, a small library consisting of cinchonidine, cinchonine (CN) and their close derivatives and analogues was explored for antimicrobial properties against the planktonic and biofilm lifestyles of S. aureus.
The compound library was first evaluated for its capacity to exert antimicrobial activity against planktonic S. aureus ( Figure 1A) . The list of all tested compounds is presented in Supplementary Table  S1 . Bacterial growth was monitored by automated turbidity measurements in the presence of the compounds (40 µM) every 15 minutes during 18 hours. No antimicrobial effect was registered by Figure 1B , the preventive effect on biofilm formation is measured and the correlation between the results obtained with resazurin and crystal violet stainings is shown. The positive hit in both figures is indicated with a solid red diamond symbol. Percentage of bacteria (planktonic or biofilms) left after treatments was calculated in relation to untreated (bacterial control) cells. The structure of the active hit (11-TPSCD) is presented in Figure 1C . the parental compounds of the series, cinchonidine and cinchonine, but one of the derivatives was found to prevent bacterial growth, causing no measurable turbidity in the wells after the 18 hours incubation period. The compound was 11-triphenylsilyl-10,11dihydrocinchonidine (11-TPSCD). Its structure is shown in Figure  1 , and its activity corresponds to the solid red diamond data point. The most distinctive feature of this molecule is the triphenylsilyl group in position 11, which is absent in all the other molecules of the library, except for 11-triphenylsilyl-9-O-trimethylsilyl-10,11dihydrocinchonidine [9-TMSO-11-TPSCD]. However, in contrast to this compound, 11-TPSCD has a free OH group in position 9 that is blocked in 9-TMSO-11-TPSCD by a trimethylsilyl group. Apparently these two structural features are crucial for the high activity of 11-TPSCD, in contrast to the other cinchonidine derivatives from the library. Ability of these compounds to prevent the S. aureus biofilm formation was also examined ( Figure 1B ). Formation of biofilms in 96-well plates was monitored after 18 hours, using the resazurin and crystal violet assays. Resazurin is a redox dye that measures the viability of the biofilms, while crystal violet is a widely used stain for biofilm biomass [8c,9] . The concomitant decrease of both endpoints (viability and biomass) is an indication of a potentially good anti-biofilm compound, and in this case such effects were detected only upon addition of 11-TPSCD. Consequently, the potencies (IC 50 and MIC values) of 11-TPSCD were determined for planktonic as well as biofilm bacteria (Table 1) . Further attention was paid to measure the effect of 11-TPSCD on already formed (18 h) biofilms (the destruction assay), as it resembles better the scenarios that are typically encountered in clinical settings.
As displayed in Table 1 , the potency (IC 50 ) of 11-TPSCD for planktonic bacteria was shown to be 6.11 µM, which corresponded fairly well with the potency determined for the ability of the compound to prevent biofilms (6.56 µM and 2.21 µM for stainings with resazurin and crystal violet, respectively). A plausible conclusion that can be derived from these values is that 11-TPSCD can prevent biofilm formation by acting on planktonic bacteria before it has reached the surface of the microtiter well plates to start the biofilm formation process. At this stage, to exclude the possibility that this antimicrobial effect could be related to general unspecific cytotoxicity also observable in mammalian cells, 11-TPSCD was tested in GT1-7 hypothalamic immortalized cells, and results showed that the compound is well tolerated. In the presence of 10 µM of 11-TPSCD no significant changes of cell viability were detected (97.6  2.7 % of viable cells) when compared to untreated control cells.
Further on, the antimicrobial activity of the hits was found not to be limited to suspended bacteria, as it can also act on mature biofilms, according to the results obtained in the destruction assay (Table 1) . In this case the potency (IC 50 ) of 11-TPSCD was found to be higher, 212 µM (when using resazurin) and 225 µM (for crystal violet). This is a typical scenario reported for most anti-biofilm compounds, as biofilm bacteria can be up to 1000 times more resistant than their planktonic counterparts [10a] . We hypothesize that 11-TPSCD can probably permeate the biofilms and act on the viable cell core and in this way display positive effects on the viability and biomass of the biofilms. A related compound, ciprofloxacin, is a quinolone-type antibiotic known to be effective against Gram-positive and Gram-negative biofilms [7,10b,11a] . The anti-staphylococcal activity of ciprofloxacin has been reported in a wide concentration range from 0.1 µM to 97 µM against planktonic S. aureus [10a,11b,c], but the potency has been found to be lower against biofilms [10a] .
Fluorescence microscopy images ( Figure 2 ) were further taken of biofilm samples treated with 11-TPSCD at around IC 50 concentration measured in the destruction assay (215 µM). In contrast to untreated biofilms (Figure 2A ), in the biofilms exposed to 11-TPSCD ( Figure 2B ) roughly half of the biofilm population was stained green (with SYTO 9 that stains living cells), while the other half was stained red (with propidium iodide that stains dead cells). This conclusion was also supported by the quantitative measurement of the green-to-red fluorescence ratios (G/R ratio) ( Figure 2D ). The 11-TPSCD-treated sample displayed 53.4% of the G/R ratio relative to untreated biofilm samples. Reduction of the biofilm burden upon exposure to 11-TPSCD, as quantified by log reduction (log R) on both planktonic and biofilm bacteria, was additionally estimated in the prevention and destruction assays.
To calculate log R, the log 10 density of the viable cell counts (CFU/mL) of the treated and control wells are typically measured, and log R is mathematically derived from the difference of the log 10 density on the untreated bacterial samples and the log 10 density on the treated biofilms [11c]. In the prevention assay, the values of log R at 10 µM of 11-TPSCD were 2.1 for biofilms and 3.9 for the planktonic phase. On the other hand, the values of log R in the destruction assay were, at 200 µM, 2.7 for biofilm bacteria and 4.9 for the planktonic bacteria measured in the same wells. In this assay, bacteria can detach from 18 h-formed biofilms and multiply in the planktonic phase during the 24 hours period in which exposure to the compound occurs. These results indicate, in agreement with previous findings, that 11-TPSCD presumably kills both biofilms and suspended bacteria. as also ciprofloxacin, does not have an effect on the EPS layer. Thus, they supposedly belong to a category of antibiotics, as defined by Toté et al., in which no effects are seen in the EPS in spite of the positive reduction of viability [12a] . Previously, effects of antibiotics on the EPS have been typically overlooked or ignored, but the recognition of these effects has resulted in a better understanding of the parameters governing antimicrobial efficacy in clinical settings.
Finally, a comparative study was performed to investigate the chemical space occupied by 11-TPSCD, thirty quinolone antibiotics currently on the market, and the non-active compounds from the library (Figure 3 ). To conduct this comparison, ChemGPS-NP was applied, which is a principal component analysis (PCA)-based model for navigation in biologically relevant chemical space, and is particularly suited for natural and naturally-derived compounds [12c,d]. The study showed that most of the members of the quinolones (solid black circles) and the cinchona alkaloid derivatives (solid blue circles) populate a fairly similar chemical space characterized by low molecular sizes (given by PC1), high aromaticity (given by PC2) and restricted flexibility (given by PC4, not shown here). Two exceptions were identified in the library, one of which was the hit compound, 11-TPSCD, and the other the similarly structured, but not active 9-TMSO-11-TPSCD. In general, the cinchona alkaloid collection was found to locate in a more lipophilic region (given by PC3), and the same two compounds (11-TPSCD and 9-TMSO-11-TPSCD) were found to be the most hydrophobic ones. Since the inactive 9-TMSO-11-TPSCD was shown to share the same chemical space as the active 11-TPSCD, it cannot be ensured that these physico-chemical properties are the only ones explaining the antibacterial activity. However, this result does support the existence of another "active" region for quininerelated molecules outside of the one typically populated by quinolone antibiotics, which could be worth exploring in future endeavors aimed at discovering antibacterial compounds. Also, based on our findings, combining 11-TPSCD with other molecules targeting the EPS, such as dispersin B [13a] , could improve the antibiofilm efficacy. As it stands, the ability of 11-TPSCD to prevent biofilm development makes it already a promising natural-derived agent to pre-condition medically relevant surfaces, for instance catheters or implants.
Experimental
Chemical library: The compounds 11-TPSCD and 9-TMSO-11-TPSCD were prepared as described in [13b] . For sources of all other compounds in the library and a list of all the structures tested, please refer to Supplementary Table S1 . The compounds were dissolved in DMSO and stored as 20 mM stock solutions at -20°C.
Bacterial growth in planktonic and biofilms:
The biofilm producing strain Staphylococcus aureus (ATCC 25923) was provided by the Faculty of Pharmacy, University of Helsinki, Finland. Bacteria were cultured in tryptic soy broth under aerobic conditions at 37°C and 200 rpm shaking to reach exponential growth, up to a concentration of 10 8 colony-forming units per mL (CFU/mL). To promote biofilm formation, a bacterial suspension (10 6 CFU/ml, 200 μL/well) was added into sterile, flat-bottomed, 96-well polystyrene micro well plates, which were incubated for 18 h under aerobic conditions (37°C, 200 rpm shaking). During screening of the preventive anti-biofilm activity, the compounds (40 µM) were added at the same time as the bacterial suspension into the wells. In the destruction assay the biofilms were first formed for 18 h, and the planktonic solution in each well was replaced with fresh TSB containing the compound (40 µM) and incubated for 24 h (37°C, 200 rpm shaking).
Biofilm quantification assays:
For measuring the presence of viable cells and the total biomass in the wells, resazurin staining and crystal violet were used respectively using protocols that have been described earlier [14, 15] .
Follow-up studies of the active cinchonidine derivative (11-TPSCD):
For potencies and MIC values, concentrations ranging from 1 µM to 30 µM were tested for activity against planktonic bacteria and prevention of biofilms. In destruction, concentrations from 100 µM to 400 µM were used. Potencies (IC 50 values) were determined by non-linear regression curve fitting (with variable slope) using GraphPad software, Prism 5.0c for Mac OS X, USA (2009). To determine the reduction of the bacterial concentration caused by the active hit, log Reduction, log R, was measured. Log R of planktonic bacteria was measured by removing the planktonic phase of treated and untreated wells, serially diluting it in TSB and plating on TSA. To determine the log R on biofilms, the treated and untreated wells were scraped off vigorously, the bacteria serially diluted and plated on TSA. Both approaches were performed for both prevention of biofilms and destruction of mature biofilms.
For determination of the effect on the EPS, the WGA method was conducted, as originally described in [12b]. Prior to adding the stain, the wells were washed once with sterile PBS, then 200 L of 5 µg/mL WGA (Molecular Probes Inc, US) in PBS was added and the biofilms were incubated for 2 h at 4ºC in the dark. After removing the unbound dye, plates were washed 3 times with PBS, air-dried for 15 min (RT) and the bound probe was solubilized with 200 L of 33% acetic acid. Plates were covered with strip caps and sonicated 2 times for 30 s with 1 h incubation period at 37ºC in between. Then, fluorescence at  excitation =495 nm and  emission =520 nm was measured. For quantifying the green-to-red fluorescence ratio (G/R ratio) in mature biofilms treated with 11-TPSCD (215 µM) the commercial bacterial viability kit LIVE/DEAD ® BacLight TM (Molecular Probes Inc, US) was used, which contains SYTO 9 (stains viable cells green) and propidium iodide (stains dead cells red). Final concentrations of the probes (added as an equal mixture diluted in water, 200 µL/well) were 5 µM and 30 µM, respectively, and incubated in darkness for 15 min (RT). Fluorescence was measured at excitation/emission wavelengths 485/535 nm and 485/635 nm for SYTO 9 and propidium iodide, respectively.
